| Autor: |
Paul Cockwell, Derek Kyte, Melanie Calvert, Louise J Jackson, Gary Price, Natalie J Ives, Jon Bishop, Mary Dutton, Elizabeth Brettell, Helen Eddington, Gabby Hadley, Stephanie Stringer, Rav Verdi, Judi Waters, Keeley Sharpe, Nicola Anderson, Andrew Bissell, Marie Chadburn, Elliot Forster, Sonia O'Brien, Adrian Wilcockson |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
BMJ Open, Vol 12, Iss 3 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2044-6055 |
| DOI: |
10.1136/bmjopen-2021-050610 |
| Popis: |
Objectives The use of routine remote follow-up of patients with chronic kidney disease (CKD) is increasing exponentially. It has been suggested that online electronic patient-reported outcome measures (ePROMs) could be used in parallel, to facilitate real-time symptom monitoring aimed at improving outcomes. We tested the feasibility of this approach in a pilot trial of ePROM symptom monitoring versus usual care in patients with advanced CKD not on dialysis.Design A 12-month, parallel, pilot randomised controlled trial (RCT) and qualitative substudy.Setting and participants Queen Elizabeth Hospital Birmingham, UK. Adult patients with advanced CKD (estimated glomerular filtration rate ≥6 and ≤15 mL/min/1.73 m2, or a projected risk of progression to kidney failure within 2 years ≥20%).Intervention Monthly online ePROM symptom reporting, including automated feedback of tailored self-management advice and triggered clinical notifications in the advent of severe symptoms. Real-time ePROM data were made available to the clinical team via the electronic medical record.Outcomes Feasibility (recruitment and retention rates, and acceptability/adherence to the ePROM intervention). Health-related quality of life, clinical data (eg, measures of kidney function, kidney failure, hospitalisation, death) and healthcare utilisation.Results 52 patients were randomised (31% of approached). Case report form returns were high (99.5%), as was retention (96%). Overall, 73% of expected ePROM questionnaires were received. Intervention adherence was high beyond 90 days (74%) and 180 days (65%); but dropped beyond 270 days (46%). Qualitative interviews supported proof of concept and intervention acceptability, but highlighted necessary changes aimed at enhancing overall functionality/scalability of the ePROM system.Limitations Small sample size.Conclusions This pilot trial demonstrates that patients are willing to be randomised to a trial assessing ePROM symptom monitoring. The intervention was considered acceptable; though measures to improve longer-term engagement are needed. A full-scale RCT is considered feasible.Trial registration number ISRCTN12669006 and the UK NIHR Portfolio (CPMS ID: 36497). |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
